Trial Profile
Phase II Study of the PARP Inhibitor Talazoparib in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Bladder cancer; Carcinoma; Cholangiocarcinoma; Sarcoma; Solid tumours
- Focus Therapeutic Use
- 14 Jun 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 14 Jun 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2025.
- 21 Feb 2022 Status changed from recruiting to active, no longer recruiting.